biostudies-literaturePuccini AGloria Borges Wunderglo FoundationDaniel Butler Research FundDhont Family FoundationNational Cancer InstituteUehara Memorial FoundationNCI NIH HHSSwiss Cancer League138-147https://www.ebi.ac.uk/biostudies/studies/S-EPMC6436973biostudies-literatureUnknown111<h4>Background</h4>CpG island DNA hypermethylation and global DNA hypomethylation are hallmark characteristics of colorectal cancer (CRC). Therefore, we aim to explore the effect of genetic variations within the genes that regulate the DNA methylation and demethylation pathways on outcomes in patients with metastatic CRC (mCRC) treated with first-line therapy and enrolled in three independent, randomised, open-label clinical trials.<h4>Methods</h4>A total of 884 patients with mCRC enrolled in TRIBE, MAVERICC and FIRE-3 trials were included. Single-nucleotide polymorphisms (SNPs) within genes involved in DNA methylation and demethylation pathways were analysed. The prognostic value of each SNP across all treatment arms was quantified using the inverse-variance-weighted effect size, a meta-aEuropean journal of cancer (Oxford, England : 1990)Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.PMC6436973P30 CA014089201630045P30CA014089BIL KLS-3334-02-2014Puccini ALoupakis FLenz HJBattaglin FMumenthaler SMNaseem MZhang WSalhia BTogunaka RMillstein JHeinemann VStintzing SLiang GMancao CCao SBerger MDCremolini CSoni SWeisenberger DJFalcone AfalseImpact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.<h4>Background</h4>CpG island DNA hypermethylation and global DNA hypomethylation are hallmark characteristics of colorectal cancer (CRC). Therefore, we aim to explore the effect of genetic variations within the genes that regulate the DNA methylation and demethylation pathways on outcomes in patients with metastatic CRC (mCRC) treated with first-line therapy and enrolled in three independent, randomised, open-label clinical trials.<h4>Methods</h4>A total of 884 patients with mCRC enrolled in TRIBE, MAVERICC and FIRE-3 trials were included. Single-nucleotide polymorphisms (SNPs) within genes involved in DNA methylation and demethylation pathways were analysed. The prognostic value of each SNP across all treatment arms was quantified using the inverse-variance-weighted effect size, a meta-a2019-01-01T00:00:00Z2019 Apr2026-04-28T23:01:06.172Z2020-05-22T14:48:11ZS-EPMC64369733085242010.1016/j.ejca.2019.01.105